Search

Your search keyword '"Le-Rademacher, Jennifer"' showing total 727 results
Start Over Author "Le-Rademacher, Jennifer"
727 results on '"Le-Rademacher, Jennifer"'

201. Post-Transplant Outcomes in High-Risk Compared with Non–High-Risk Multiple Myeloma: A CIBMTR Analysis

Author

Scott, Emma C., primary, Hari, Parameswaran, additional, Sharma, Manish, additional, Le-Rademacher, Jennifer, additional, Huang, Jiaxing, additional, Vogl, Dan, additional, Abidi, Muneer, additional, Beitinjaneh, Amer, additional, Fung, Henry, additional, Ganguly, Siddhartha, additional, Hildebrandt, Gerhard, additional, Holmberg, Leona, additional, Kalaycio, Matt, additional, Kumar, Shaji, additional, Kyle, Robert, additional, Lazarus, Hillard, additional, Lee, Cindy, additional, Maziarz, Richard T., additional, Meehan, Kenneth, additional, Mikhael, Joseph, additional, Nishihori, Taiga, additional, Ramanathan, Muthalagu, additional, Usmani, Saad, additional, Tay, Jason, additional, Vesole, David, additional, Wirk, Baldeep, additional, Yared, Jean, additional, Savani, Bipin N., additional, Gasparetto, Cristina, additional, Krishnan, Amrita, additional, Mark, Tomer, additional, Nieto, Yago, additional, and D'Souza, Anita, additional

Published
2016
Full Text
View/download PDF

203. Autologous hematopoietic cell transplantation for HIV-related lymphoma: results of the BMT CTN 0803/AMC 071 trial

Author

Alvarnas, Joseph C., primary, Le Rademacher, Jennifer, additional, Wang, Yanli, additional, Little, Richard F., additional, Akpek, Gorgun, additional, Ayala, Ernesto, additional, Devine, Steven, additional, Baiocchi, Robert, additional, Lozanski, Gerard, additional, Kaplan, Lawrence, additional, Noy, Ariela, additional, Popat, Uday, additional, Hsu, Jack, additional, Morris, Lawrence E., additional, Thompson, Jason, additional, Horowitz, Mary M., additional, Mendizabal, Adam, additional, Levine, Alexandra, additional, Krishnan, Amrita, additional, Forman, Stephen J., additional, Navarro, Willis H., additional, and Ambinder, Richard, additional

Published
2016
Full Text
View/download PDF

204. Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies

Author

Pasquini, Marcelo C., primary, Le-Rademacher, Jennifer, additional, Zhu, Xiaochun, additional, Artz, Andrew, additional, DiPersio, John, additional, Fernandez, Hugo F., additional, Mineishi, Shin, additional, Kamishohara, Masaru, additional, Mehta, Jayesh, additional, Nakamura, Yuki, additional, Ratanatharathorn, Voravit, additional, Sobecks, Ronald, additional, Burkart, Jeanne, additional, and Bredeson, Christopher, additional

Published
2016
Full Text
View/download PDF

205. Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes

Author

Flowers, Christopher R., primary, Costa, Luciano J., additional, Pasquini, Marcelo C., additional, Le-Rademacher, Jennifer, additional, Lill, Michael, additional, Shore, Tsiporah B., additional, Vaughan, William, additional, Craig, Michael, additional, Freytes, Cesar O., additional, Shea, Thomas C., additional, Horwitz, Mitchell E., additional, Fay, Joseph W., additional, Mineishi, Shin, additional, Rondelli, Damiano, additional, Mason, James, additional, Braunschweig, Ira, additional, Ai, Weiyun, additional, Yeh, Rosa F., additional, Rodriguez, Tulio E., additional, Flinn, Ian, additional, Comeau, Terrance, additional, Yeager, Andrew M., additional, Pulsipher, Michael A., additional, Bence-Bruckler, Isabelle, additional, Laneuville, Pierre, additional, Bierman, Philip, additional, Chen, Andy I., additional, Kato, Kazunobu, additional, Wang, Yanlin, additional, Xu, Cong, additional, Smith, Angela J., additional, and Waller, Edmund K., additional

Published
2016
Full Text
View/download PDF

209. Phase II Study of Treosulfan/Fludarabine/ Low Dose Total Body Irradiation As a Preparative Regimen for Children with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Undergoing Allogeneic Hematopoietic Cell Transplantation

Author

Nemecek, Eneida R., primary, Adams, Alexia J., additional, Shaw, Bronwen E., additional, Kiefer, Deidre M., additional, Le-Rademacher, Jennifer G., additional, Levine, John E., additional, Yanik, Gregory A., additional, Leung, Wing H., additional, Talano, Julie-An M., additional, Haut, Paul R., additional, Delgado, David C., additional, Kapoor, Neena, additional, Petrovic, Aleksandra, additional, Adams, Roberta H., additional, Hanna, Rabi, additional, Rangarajan, Hemalatha G., additional, Dalal, Jignesh D., additional, Chewning, Joseph H., additional, Verneris, Michael R., additional, Epstein, Stacy S., additional, Pulsipher, Michael A., additional, and Delaney, Colleen, additional

Published
2016
Full Text
View/download PDF

211. Symbolic covariance matrix for interval-valued variables and its application to principal component analysis

Author

Billard, Lynne, Košmelj, Katarina, and Le-Rademacher, Jennifer

Subjects
Statistics and Probability, Social Sciences (miscellaneous)
Abstract

In the last two decades, principal component analysis (PCA) was extended to interval-valued data; several adaptations of the classical approach are known from the literature. Our approach is based on the symbolic covariance matrix Cov for the interval-valued variables proposed by Billard (2008). Its crucial advantage, when compared to other approaches, is that it fully utilizes all the information in the data. The symbolic covariance matrix can be decomposed into a within part CovW and a between part CovB. We propose a further insight into the PCA results: the proportion of variance explained due to the within information and the proportion of variance explained due to the between information can be calculated. Additionally, we suggest PCA on CovB and CovW to be done to obtain deeper insights into the data under study. In the case study presented, the information gain when performing PCA on the intervals instead of the interval midpoints (conditionally the means) is about 45%. It turns out that, for these data, the uniformity assumption over intervals does not hold and so analysis of the data represented by histogram-valued variables is suggested.

Published
2014
Full Text
View/download PDF

212. What occurs in the other 20% of cancer patients with chemotherapy-induced nausea and vomiting (CINV)? A single-institution qualitative study.

Author

Childs, Daniel S., Looker, Sherry, Le-Rademacher, Jennifer, Ridgeway, Jennifer L., Breitkopf, Carmen Radecki, and Jatoi, Aminah

Subjects
CANCER patients, CHEMOTHERAPY complications, NAUSEA, VOMITING, QUALITATIVE research
Abstract

Purpose: Despite recent advances in prophylaxis and management, 20% of patients who receive moderately to severely emetogenic chemotherapy continue to experience nausea and vomiting. Relying on patients' own words, this study sought to capture and characterize the lived experience with chemotherapy-induced nausea and vomiting (CINV) for this important subgroup of patients.Methods: Solid tumor patients with a history of poorly controlled CINV provided informed consent and participated in a semi-structured interview, which was audio-recorded and transcribed. After data saturation, enrollment ceased, and inductive, qualitative analytic methods were employed.Results: The median age of the 20 enrolled patients was 56 years (range 27-83) with an equal gender split; half had gastrointestinal cancers. Two themes emerged. First, CINV is severe and multidimensional: "It's like shredding your muscles… It's doing it over and over again." This symptom complex has psychosocial implications: "Isolation is a big thing." Financial toxicity is also implicated: "I use [an antiemetic] when I feel like it is absolutely necessary because it is so expensive I cannot afford it anyway." The second theme is underreporting of symptoms. Patients seemed to accept N/V as part of treatment and were therefore less forthcoming: "God, if you're pumping poison in your system, you gotta expect some side effects."Conclusions: These vivid data should motivate investigators to continue conducting clinical trials CINV and should remind healthcare providers about the importance of patient education on the availability of therapy for breakthrough symptomatology. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

214. Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622).

Author

Feliciano, Josephine L., Le-Rademacher, Jennifer G., Gajra, Ajeet, Edelman, Martin J., Zemla, Tyler, McMurray, Ryan, Chen, Hongbin, Hurria, Arti, Muss, Hyman, Cohen, Harvey J., Lilenbaum, Rogerio, and Jatoi, Aminah

Abstract

Objective This study sought to define the role of first-line platinum-based doublet chemotherapy in older patients with non-small cell lung cancer (NSCLC). Materials and Methods We analyzed three first-line NSCLC trials: CALGB 9730, CALGB 30203, and CALGB 30801, which tested carboplatin and paclitaxel; carboplatin and gemcitabine; and carboplatin with either pemetrexed or gemcitabine, respectively. Overall survival was the primary endpoint. Age-based comparisons with a cutpoint of 65 years were performed with Cox proportional hazards models with adjustments for sex, tumor histology, cancer stage, chemotherapy, and smoking history and after stratifying by performance score. Secondary endpoints were grade 3–5 adverse events, chemotherapy cycles completed, and whether toxicity prompted chemotherapy discontinuation. Results 730 patients were included; 337 (46%) were 65+ years of age. No statistically significant difference in survival was observed for older (≥65) versus younger patients (HR = 1.096; 95% CI = (0.94, 1.28); p  = 0.25). A trend emerged with increased odds of a grade 3–5 adverse event for patients ≥65 years versus <65 years (OR = 1.52; 95% CI = (0.99, 2.31); p  = 0.05). The proportion of completed chemotherapy cycles was marginally lower in older patients (difference = −5%; 95% CI = (−9, 0.2); p  = 0.06) for those ≥65 years versus <65 years, but no statistically significant difference occurred in the rate of chemotherapy discontinuation for toxicity (OR = 1.4; 95% CI = (0.85, 2.19); p  = 0.21) for patients ≥65 years versus <65 years. A cutpoint of 70 years yielded similar results. Conclusion These findings support carboplatin doublet-based chemotherapy in select older patients with advanced NSCLC. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

215. Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711).

Author

Gajra, Ajeet, Zemla, Tyler J., Jatoi, Aminah, Feliciano, Josephine L., Wong, Melisa L., Chen, Hongbin, Maggiore, Ronald, McMurray, Ryan P., Hurria, Arti, Muss, Hyman B., Cohen, Harvey J., Lafky, Jacqueline, Edelman, Martin J., Lilenbaum, Rogerio, and Le-Rademacher, Jennifer G.

Published
2018
Full Text
View/download PDF

216. Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Author

McBane, Robert D., Wysokinski, Waldemar E., Le‐Rademacher, Jennifer G., Zemla, Tyler, Ashrani, Aneel, Tafur, Alfonso, Perepu, Usha, Anderson, Daniel, Gundabolu, Krishna, Kuzma, Charles, Perez Botero, Juliana, Leon Ferre, Roberto A., Henkin, Stanislav, Lenz, Charles J., Houghton, Damon E., Vishnu, Prakash, and Loprinzi, Charles L.

Abstract

Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, limited data support its use in cancer patients.

Published
2020
Full Text
View/download PDF

217. Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60–75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study

Author

Ustun, Celalettin, Le-Rademacher, Jennifer, Wang, Hai-Lin, Othus, Megan, Sun, Zhuoxin, Major, Brittny, Zhang, Mei-Jie, Storrick, Elizabeth, Lafky, Jacqueline M., Chow, Selina, Mrózek, Krzysztof, Attar, Eyal C., Nand, Such, Bloomfield, Clara D., Cripe, Larry D., Tallman, Martin S., Appelbaum, Frederick, Larson, Richard A., Marcucci, Guido, Roboz, Gail J., Uy, Geoffrey L., Stone, Richard M., Jatoi, Aminah, Shea, Thomas C., de Lima, Marcos, Foran, James M., Sandmaier, Brenda M., Litzow, Mark R., Erba, Harry P., Hurria, Arti, Weisdorf, Daniel J., and Artz, Andrew S.

Abstract

The preferred post-remission therapy for older patients with acute myeloid leukemia (AML) in first complete remission (CR1) remains uncertain. In this retrospective, multicenter study, we compared the outcomes for older AML patients (age 60–77 years) receiving allogeneic hematopoietic cell transplantation (alloHCT) (n= 431) with those treated on prospective National Clinical Trials Network induction and nontransplantation chemotherapy (CT) consolidation trials (n= 211). AlloHCT patients were younger (median age: 64.2 versus 67.9 years, p< 0.001), but more frequently had high-risk AML (high WBC, secondary AML, and unfavorable cytogenetics). Overall survival (OS) was worse in alloHCT during the first 9 months after CR1 (HR = 1.52, p= 0.02), but was significantly better thereafter (HR = 0.53, p< 0.0001) relative to CT. Treatment-related mortality (TRM) following HCT was worse in the first 9 months (HR = 2.8, 95% CI: 1.5–5.2, p= 0.0009), while post-HCT relapse was significantly less frequent beyond 9 months (HR = 0.42, 95% CI: 0.29–0.61, p< 0.0001). Despite higher early TRM, alloHCT recipients had superior long-term OS [29% (24–34%) versus CT 13.8% (9–21%) at 5 years]. Although this is a retrospective analysis with potential biases, it indicates that alloHCT led to heightened early risks from TRM, yet reduced relapse and superior long-term survival relative to CT in older AML patients in CR1.

Published
2019
Full Text
View/download PDF

218. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells

Author

Chen, Yi-Bin, Le-Rademacher, Jennifer, Brazauskas, Ruta, Kiefer, Deidre M., Hamadani, Mehdi, DiPersio, John F., Litzow, Mark R., Craig, Michael, Horwitz, Mitchell E., Artz, Andrew S., McClune, Brian L., Fernandez, Hugo F., Duong, Hien Kim, Kobusingye, Hati, Proue, Mandi, Drexler, Rebecca J., Horowitz, Mary M., Shaw, Bronwen E., Miller, John P., Hosoba, Sakura, Waller, Edmund K., and Devine, Steven M.

Abstract

Plerixafor, a direct antagonist of CXCR4/stromal-derived factor 1, can safely and rapidly mobilize allografts without the use of granulocyte colony-stimulating factor (G-CSF). We conducted a phase 2, multicenter, prospective study of plerixafor-mobilized HLA-identical sibling allografts for allogeneic hematopoietic cell transplantation in recipients with hematological malignancies. Donors (n = 64) were treated with subcutaneous plerixafor (240 µg/kg) and started leukapheresis (LP) 4 hours later. The primary objective was to determine the proportion of donors who were successfully mobilized: defined as collection of ≥2.0 × 106 CD34+ cells per kilogram recipient weight in ≤2 LP sessions. Recipients subsequently received reduced intensity (RIC; n = 33) or myeloablative (MAC; n = 30) conditioning. Sixty-three of 64 (98%) donors achieved the primary objective. The median CD34+ cell dose per kilogram recipient weight collected within 2 days was 4.7 (0.9-9.6). Plerixafor was well tolerated with only grade 1 or 2 drug-related adverse events noted. Bone pain was not observed. Plerixafor-mobilized grafts engrafted promptly. One-year progression-free and overall survivals were 53% (95% confidence interval [CI], 36% to 71%) and 63% (95% CI, 46% to 79%) for MAC and 64% (95% CI, 47% to 79%) and 70% (95% CI, 53% to 84%) for RIC recipients, respectively. Donor toxicity was reduced relative to G-CSF mobilized related donors. This is the first multicenter trial to demonstrate that, as an alternative to G-CSF, plerixafor rapidly and safely mobilizes sufficient numbers of CD34+ cells from matched sibling donors for HCT. Engraftment was prompt, and outcomes in recipients were encouraging. This trial was registered at clinicaltrials.gov as #NCT01696461.

Published
2019
Full Text
View/download PDF

220. Corrigendum to ‘Extending Venous Thromboembolism Secondary Prevention with Apixaban in Cancer Patients. The EVE Trial’

Author

McBane, Robert D., Loprinzi, Charles L., Zemla, Tyler, Tafur, Alfonso, Sanfilippo, Kristen, Liu, Jane Jijun, Garcia, David A., Heun, James, Gundabolu, Krishna, Onitilo, Adedayo A., Perepu, Usha, Drescher, Monic R., Henkin, Stanislav, Houghton, Damon, Ashrani, Aneel, Billett, Henny, Mooberry, Micah J., McCue, Shaylene A., Lee, Minji K., Le-Rademacher, Jennifer G., and Wysokinski, Waldemar E.

Published
2024
Full Text
View/download PDF

221. Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure

Author

Ayas, Mouhab, Eapen, Mary, Le-Rademacher, Jennifer, Carreras, Jeanette, Abdel-Azim, Hisham, Alter, Blanche P., Anderlini, Paolo, Battiwalla, Minoo, Bierings, Marc, Buchbinder, David K., Bonfim, Carmem, Camitta, Bruce M., Fasth, Anders L., Gale, Robert Peter, Lee, Michelle A., Lund, Troy C., Myers, Kasiani C., Olsson, Richard F., Page, Kristin M., Prestidge, Tim D., Radhi, Mohamed, Shah, Ami J., Schultz, Kirk R., Wirk, Baldeep, Wagner, John E., Deeg, H. Joachim, Ayas, Mouhab, Eapen, Mary, Le-Rademacher, Jennifer, Carreras, Jeanette, Abdel-Azim, Hisham, Alter, Blanche P., Anderlini, Paolo, Battiwalla, Minoo, Bierings, Marc, Buchbinder, David K., Bonfim, Carmem, Camitta, Bruce M., Fasth, Anders L., Gale, Robert Peter, Lee, Michelle A., Lund, Troy C., Myers, Kasiani C., Olsson, Richard F., Page, Kristin M., Prestidge, Tim D., Radhi, Mohamed, Shah, Ami J., Schultz, Kirk R., Wirk, Baldeep, Wagner, John E., and Deeg, H. Joachim

Abstract

A second allogeneic hematopoietic cell transplantation (HCT) is the sole salvage option for individuals who develop graft failure after their first HCT. Data on outcomes after second HCT in patients with Fanconi anemia (FA) are scarce. Here we report outcomes after second allogeneic HCT for FA (n = 81). The indication for second HCT was graft failure after the first HCT. Transplantations were performed between 1990 and 2012. The timing of the second HCT predicted subsequent graft failure and survival. Graft failure was high when the second HCT was performed less than 3 months from the first. The 3-month probability of graft failure was 69% when the interval between the first HCT and second HCT was less than 3 months, compared with 23% when the interval was longer (P < .001). Consequently, the 1-year survival rate was substantially lower when the interval between the first and second HCTs was less than 3 months compared with longer (23% vs 58%; P = .001). The corresponding 5-year probability of survival was 16% and 45%, respectively (P = .006). Taken together, these data suggest that fewer than one-half of patients with FA undergoing a second HCT for graft failure are long-term survivors. There is an urgent need to develop strategies to reduce the rate of graft failure after first HCT.

Published
2015
Full Text
View/download PDF

222. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission : A Report from the Center for International Blood and Marrow Transplant Research

Author

Burke, Michael J., Verneris, Michael R., Le Rademacher, Jennifer, He, Wensheng, Abdel-Azim, Hisham, Abraham, Allistair A., Auletta, Jeffery J., Ayas, Mouhab, Brown, Valerie I., Cairo, Mitchell S., Chan, Ka Wah, Diaz Perez, Miguel A., Dvorak, Christopher C., Egeler, R. Maarten, Eldjerou, Lamis, Frangoul, Haydar, Guilcher, Gregory M. T., Hayashi, Robert J., Ibrahim, Ahmed, Kasow, Kimberly A., Leung, Wing H., Olsson, Richard F., Pulsipher, Michael A., Shah, Niketa, Shah, Nirali N., Thiel, Elizabeth, Talano, Julie-An, Kitko, Carrie L., Burke, Michael J., Verneris, Michael R., Le Rademacher, Jennifer, He, Wensheng, Abdel-Azim, Hisham, Abraham, Allistair A., Auletta, Jeffery J., Ayas, Mouhab, Brown, Valerie I., Cairo, Mitchell S., Chan, Ka Wah, Diaz Perez, Miguel A., Dvorak, Christopher C., Egeler, R. Maarten, Eldjerou, Lamis, Frangoul, Haydar, Guilcher, Gregory M. T., Hayashi, Robert J., Ibrahim, Ahmed, Kasow, Kimberly A., Leung, Wing H., Olsson, Richard F., Pulsipher, Michael A., Shah, Niketa, Shah, Nirali N., Thiel, Elizabeth, Talano, Julie-An, and Kitko, Carrie L.

Abstract

Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated with chemotherapy alone, and outcomes after allogeneic hematopoietic cell transplantation (HCT) is not well described. Two hundred twenty-nine children with T-ALL in second complete remission (CR2) received an HCT after myeloablative conditioning between 2000 and 2011 and were reported to the Center for International Blood and Marrow Transplant Research. Median age was 10 years (range, 2 to 18). Donor source was umbilical cord blood (26%), matched sibling bone marrow (38%), or unrelated bone marrow/peripheral blood (36%). Acute (grades II to IV) and chronic graft-versus-host disease occurred in, respectively, 35% (95% confidence interval [CI], 27% to 45%) and 26% (95% CI, 20% to 33%) of patients. Transplant-related mortality at day 100 and 3-year relapse rates were 13% (95% CI, 9% to 18%) and 30% (95% CI, 24% to 37%), respectively. Three-year overall survival and disease-free survival rates were 48% (95% CI, 41% to 55%) and 46% (95% CI, 39% to 52%), respectively. In multivariate analysis, patients with bone marrow relapse, with or without concurrent extramedullary relapse before HCT, were most likely to relapse (hazard ratio, 3.94; P =.005) as compared with isolated extramedullary disease. In conclusion, HCT for pediatric T-ALL in CR2 demonstrates reasonable and durable outcomes, and consideration for HCT is warranted. (c) 2015 American Society for Blood and Marrow Transplantation.

Published
2015
Full Text
View/download PDF

223. Hematopoietic stem cell transplantation for infantile osteopetrosis

Author

Orchard, Paul J., Fasth, Anders L., Le Rademacher, Jennifer L., He, Wensheng, Boelens, Jaap Jan, Horwitz, Edwin M., Al-Seraihy, Amal, Ayas, Mouhab, Bonfim, Carmem M., Boulad, Farid, Lund, Troy, Buchbinder, David K., Kapoor, Neena, OBrien, Tracey A., Perez, Miguel A Diaz, Veys, Paul A., Eapen, Mary, Orchard, Paul J., Fasth, Anders L., Le Rademacher, Jennifer L., He, Wensheng, Boelens, Jaap Jan, Horwitz, Edwin M., Al-Seraihy, Amal, Ayas, Mouhab, Bonfim, Carmem M., Boulad, Farid, Lund, Troy, Buchbinder, David K., Kapoor, Neena, OBrien, Tracey A., Perez, Miguel A Diaz, Veys, Paul A., and Eapen, Mary

Published
2015

224. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research.

Author

Burke, Michael J, Burke, Michael J, Verneris, Michael R, Le Rademacher, Jennifer, He, Wensheng, Abdel-Azim, Hisham, Abraham, Allistair A, Auletta, Jeffery J, Ayas, Mouhab, Brown, Valerie I, Cairo, Mitchell S, Chan, Ka Wah, Diaz Perez, Miguel A, Dvorak, Christopher C, Egeler, R Maarten, Eldjerou, Lamis, Frangoul, Haydar, Guilcher, Gregory MT, Hayashi, Robert J, Ibrahim, Ahmed, Kasow, Kimberly A, Leung, Wing H, Olsson, Richard F, Pulsipher, Michael A, Shah, Niketa, Shah, Nirali N, Thiel, Elizabeth, Talano, Julie-An, Kitko, Carrie L, Burke, Michael J, Burke, Michael J, Verneris, Michael R, Le Rademacher, Jennifer, He, Wensheng, Abdel-Azim, Hisham, Abraham, Allistair A, Auletta, Jeffery J, Ayas, Mouhab, Brown, Valerie I, Cairo, Mitchell S, Chan, Ka Wah, Diaz Perez, Miguel A, Dvorak, Christopher C, Egeler, R Maarten, Eldjerou, Lamis, Frangoul, Haydar, Guilcher, Gregory MT, Hayashi, Robert J, Ibrahim, Ahmed, Kasow, Kimberly A, Leung, Wing H, Olsson, Richard F, Pulsipher, Michael A, Shah, Niketa, Shah, Nirali N, Thiel, Elizabeth, Talano, Julie-An, and Kitko, Carrie L

Abstract

Survival for children with relapsed T cell acute lymphoblastic leukemia (T-ALL) is poor when treated with chemotherapy alone, and outcomes after allogeneic hematopoietic cell transplantation (HCT) is not well described. Two hundred twenty-nine children with T-ALL in second complete remission (CR2) received an HCT after myeloablative conditioning between 2000 and 2011 and were reported to the Center for International Blood and Marrow Transplant Research. Median age was 10 years (range, 2 to 18). Donor source was umbilical cord blood (26%), matched sibling bone marrow (38%), or unrelated bone marrow/peripheral blood (36%). Acute (grades II to IV) and chronic graft-versus-host disease occurred in, respectively, 35% (95% confidence interval [CI], 27% to 45%) and 26% (95% CI, 20% to 33%) of patients. Transplant-related mortality at day 100 and 3-year relapse rates were 13% (95% CI, 9% to 18%) and 30% (95% CI, 24% to 37%), respectively. Three-year overall survival and disease-free survival rates were 48% (95% CI, 41% to 55%) and 46% (95% CI, 39% to 52%), respectively. In multivariate analysis, patients with bone marrow relapse, with or without concurrent extramedullary relapse before HCT, were most likely to relapse (hazard ratio, 3.94; P = .005) as compared with isolated extramedullary disease. In conclusion, HCT for pediatric T-ALL in CR2 demonstrates reasonable and durable outcomes, and consideration for HCT is warranted.

Published
2015

225. Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure

Author

Haematologie, Child Health, Regenerative Medicine and Stem Cells, Ayas, Mouhab, Eapen, Mary, Le-Rademacher, Jennifer, Carreras, Jeanette, Abdel-Azim, Hisham, Alter, Blanche P., Anderlini, Paolo, Battiwalla, Minoo, Bierings, MB, Buchbinder, David K., Bonfim, Carmem, Camitta, Bruce M., Fasth, Anders L., Gale, Robert Peter, Lee, Michelle A., Lund, Troy C., Myers, Kasiani C., Olsson, Richard F., Page, Kristin M., Prestidge, Tim D., Radhi, Mohamed, Shah, Ami J., Schultz, Kirk R., Wirk, Baldeep, Wagner, John E., Deeg, H. Joachim, Haematologie, Child Health, Regenerative Medicine and Stem Cells, Ayas, Mouhab, Eapen, Mary, Le-Rademacher, Jennifer, Carreras, Jeanette, Abdel-Azim, Hisham, Alter, Blanche P., Anderlini, Paolo, Battiwalla, Minoo, Bierings, MB, Buchbinder, David K., Bonfim, Carmem, Camitta, Bruce M., Fasth, Anders L., Gale, Robert Peter, Lee, Michelle A., Lund, Troy C., Myers, Kasiani C., Olsson, Richard F., Page, Kristin M., Prestidge, Tim D., Radhi, Mohamed, Shah, Ami J., Schultz, Kirk R., Wirk, Baldeep, Wagner, John E., and Deeg, H. Joachim

Published
2015

226. Hematopoietic stem cell transplantation for infantile osteopetrosis

Author

CTI Nierkens, Regenerative Medicine and Stem Cells, Child Health, Infection & Immunity, SCT onderzoek, Orchard, Paul J., Fasth, Anders L., Le Rademacher, Jennifer L., He, Wensheng, Boelens, Jaap Jan, Horwitz, Edwin M., Al-Seraihy, Amal, Ayas, Mouhab, Bonfim, Carmem M., Boulad, Farid, Lund, Troy, Buchbinder, David K., Kapoor, Neena, OBrien, Tracey A., Perez, Miguel A Diaz, Veys, Paul A., Eapen, Mary, CTI Nierkens, Regenerative Medicine and Stem Cells, Child Health, Infection & Immunity, SCT onderzoek, Orchard, Paul J., Fasth, Anders L., Le Rademacher, Jennifer L., He, Wensheng, Boelens, Jaap Jan, Horwitz, Edwin M., Al-Seraihy, Amal, Ayas, Mouhab, Bonfim, Carmem M., Boulad, Farid, Lund, Troy, Buchbinder, David K., Kapoor, Neena, OBrien, Tracey A., Perez, Miguel A Diaz, Veys, Paul A., and Eapen, Mary

Published
2015

227. A Phase II Study Evaluating the Safety and Efficacy of Subcutaneous Plerixafor for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Recipients with Hematological Malignancies

Author

Chen, Yi-Bin, primary, Le-Rademacher, Jennifer, additional, Kiefer, Deidre Marie, additional, Hamadani, Mehdi, additional, DiPersio, John F., additional, Litzow, Mark R, additional, Craig, Michael, additional, Horwitz, Mitchell E., additional, Artz, Andrew, additional, McClune, Brian, additional, Waller, Edmund K, additional, Fernandez, Hugo F., additional, Duong, Hien Kim, additional, Kobusingye, Hati, additional, Proue, Mandi, additional, Drexler, Rebecca J., additional, Horowitz, Mary M., additional, Miller, John P., additional, and Devine, Steven M., additional

Published
2015
Full Text
View/download PDF

228. Results of a Phase III Randomized, Multi-Center Study of Allogeneic Stem Cell Transplantation after High Versus Reduced Intensity Conditioning in Patients with Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia (AML): Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0901

Author

Scott, Bart L, primary, Pasquini, Marcelo C., additional, Logan, Brent, additional, Wu, Juan, additional, Devine, Steve, additional, Porter, David L, additional, Maziarz, Richard T., additional, Warlick, Erica, additional, Fernandez, Hugo F., additional, Alyea, Edwin P., additional, Hamadani, Mehdi, additional, Bashey, Asad, additional, Giralt, Sergio A., additional, Leifer, Eric, additional, Geller, Nancy, additional, Le-Rademacher, Jennifer, additional, Mendizabal, Adam M., additional, Horowitz, Mary M., additional, Joachim Deeg, H., additional, and Horwitz, Mitchell E., additional

Published
2015
Full Text
View/download PDF

230. Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research

Author

Burke, Michael J., primary, Verneris, Michael R., additional, Le Rademacher, Jennifer, additional, He, Wensheng, additional, Abdel-Azim, Hisham, additional, Abraham, Allistair A., additional, Auletta, Jeffery J., additional, Ayas, Mouhab, additional, Brown, Valerie I., additional, Cairo, Mitchell S., additional, Chan, Ka Wah, additional, Diaz Perez, Miguel A., additional, Dvorak, Christopher C., additional, Egeler, R. Maarten, additional, Eldjerou, Lamis, additional, Frangoul, Haydar, additional, Guilcher, Gregory M.T., additional, Hayashi, Robert J., additional, Ibrahim, Ahmed, additional, Kasow, Kimberly A., additional, Leung, Wing H., additional, Olsson, Richard F., additional, Pulsipher, Michael A., additional, Shah, Niketa, additional, Shah, Nirali N., additional, Thiel, Elizabeth, additional, Talano, Julie-An, additional, and Kitko, Carrie L., additional

Published
2015
Full Text
View/download PDF

231. Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902)

Author

Wood, William A., primary, Le-Rademacher, Jennifer, additional, Syrjala, Karen L., additional, Jim, Heather, additional, Jacobsen, Paul B., additional, Knight, Jennifer M., additional, Abidi, Muneer H., additional, Wingard, John R., additional, Majhail, Navneet S., additional, Geller, Nancy L., additional, Rizzo, J. Douglas, additional, Fei, Mingwei, additional, Wu, Juan, additional, Horowitz, Mary M., additional, and Lee, Stephanie J., additional

Published
2015
Full Text
View/download PDF

232. Second Allogeneic Hematopoietic Cell Transplantation for Patients with Fanconi Anemia and Bone Marrow Failure

Author

Ayas, Mouhab, primary, Eapen, Mary, additional, Le-Rademacher, Jennifer, additional, Carreras, Jeanette, additional, Abdel-Azim, Hisham, additional, Alter, Blanche P., additional, Anderlini, Paolo, additional, Battiwalla, Minoo, additional, Bierings, Marc, additional, Buchbinder, David K., additional, Bonfim, Carmem, additional, Camitta, Bruce M., additional, Fasth, Anders L., additional, Gale, Robert Peter, additional, Lee, Michelle A., additional, Lund, Troy C., additional, Myers, Kasiani C., additional, Olsson, Richard F., additional, Page, Kristin M., additional, Prestidge, Tim D., additional, Radhi, Mohamed, additional, Shah, Ami J., additional, Schultz, Kirk R., additional, Wirk, Baldeep, additional, Wagner, John E., additional, and Deeg, H. Joachim, additional

Published
2015
Full Text
View/download PDF

233. Hematopoietic stem cell transplantation for infantile osteopetrosis

Author

Orchard, Paul J., primary, Fasth, Anders L., additional, Le Rademacher, Jennifer, additional, He, Wensheng, additional, Boelens, Jaap Jan, additional, Horwitz, Edwin M., additional, Al-Seraihy, Amal, additional, Ayas, Mouhab, additional, Bonfim, Carmem M., additional, Boulad, Farid, additional, Lund, Troy, additional, Buchbinder, David K., additional, Kapoor, Neena, additional, O’Brien, Tracey A., additional, Perez, Miguel A. Diaz, additional, Veys, Paul A., additional, and Eapen, Mary, additional

Published
2015
Full Text
View/download PDF

236. Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

Author

Casulo, Carla, Le-Rademacher, Jennifer, Dixon, Jesse, Salles, Gilles, Hoster, Eva, Herold, Michael, Hiddemann, Wolfgang, Sebban, Catherine, Marcus, Robert, Kimby, Eva, Hochster, Howard, Vitolo, Umberto, Gyan, Emmanuel, Ou, Fang-Shu, Nielsen, Tina, Foon, Kenneth A., Qiuan, Shi, and Flowers, Christopher

Published
2017
Full Text
View/download PDF

237. Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials.

Author

Le-Rademacher, Jennifer, Pachman, Deirdre, Qin, Rui, Ruddy, Kathryn, Banck, Michaela, Sloan, Jeff, Loprinzi, Charles, Beutler, Andreas, Kanwar, Rahul, Seisler, Drew, Abyzov, Alexej, Lavoie Smith, Ellen, Dorsey, Susan, Aaronson, Neil, Pachman, Deirdre R, Ruddy, Kathryn J, Banck, Michaela S, Lavoie Smith, Ellen M, Dorsey, Susan G, and Aaronson, Neil K

Subjects
*QUALITY of life, *CANCER patients, *OXALIPLATIN, *CARBOPLATIN, *PERIPHERAL neuropathy, *PACLITAXEL, *ANTINEOPLASTIC agents, *ORGANOPLATINUM compounds, *PHYSICIANS, *QUESTIONNAIRES, *RESEARCH funding, *TUMORS
Abstract

Purpose: Clinical practice guidelines on chemotherapy-induced peripheral neuropathy (CIPN) use the NCI Common Terminology Criteria for Adverse Events (CTCAE), while recent clinical trials employ a potentially superior measure, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN twenty-item scale (QLQ-CIPN20), a patient-reported outcome (PRO). Practitioners and researchers lack guidance, regarding how QLQ-CIPN20 results relate to the traditional CTCAE during the serial assessment of patients undergoing chemotherapy.Methods: Two large CIPN clinical trial datasets (538 patients) pairing QLQ-CIPN20 and CTCAE outcomes were analyzed using a multivariable linear mixed model with QLQ-CIPN20 score as the outcome variable, CTCAE grade as the main effect, and patient as random effect (accounting for internal correlation of serial measures).Results: The association between QLQ-CIPN20 scores and CTCAE grades was strong (p < 0.0001), whereby patients with higher CTCAE grade had worse QLQ-CIPN20 scores. Some variation of QLQ-CIPN20 scores was observed based on drug, treatment, and cycle. While there was a marked difference in the mean QLQ-CIPN20 scores between CTCAE grades, the ranges of QLQ-CIPN20 scores within each CTCAE grade were large, leading to large overlap in CIPN20 scores across CTCAE grades.Conclusions: A strong positive association of QLQ-CIPN20 scores and CTCAE grade provides evidence of convergent validity as well as practical guidance, as to how to quantitatively interpret QLQ-CIPN20 scores at the study level in terms of the traditional CTCAE. The present results also highlight an important clinical caveat, specifically, that conversion of a specific QLQ-CIPN20 score to a specific CTCAE score may not be reliable at the level of an individual patient. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

238. Overcoming obstacles in the design of cancer anorexia/weight loss trials.

Author

Le-Rademacher, Jennifer G., Crawford, Jeffrey, Evans, William J., and Jatoi, Aminah

Subjects
*CANCER patients, *ANOREXIA nervosa, *WEIGHT loss & psychology, *PREVENTION of weight loss, *CLINICAL trials
Abstract

Most advanced cancer patients suffer loss of appetite (anorexia) and loss of weight. Despite the fact that cancer anorexia and weight loss are associated with a poor prognosis and detract from quality of life, no interventions have been demonstrated to palliate this syndrome in its entirety, particularly in patients with treatment-refractory malignancies. Recently, two registration trials − one with anamorelin and another with enobosarm − failed to reach their primary endpoints, thus raising questions. Were both these agents ineffective? Alternatively, did study design issues compromise the ability of these trials to identify effective agents? Thus, this review is timely insofar it serves as an introduction to study design, offers guidance on how to test promising agents for cancer anorexia/weight loss, and provides advice for overcoming trial design obstacles. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

239. Patient-Reported Quality of Life Is an Independent Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation: A Secondary Analysis from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Author

Wood, William A., primary, Le-Rademacher, Jennifer, additional, Fei, Mingwei, additional, Logan, Brent R., additional, Syrjala, Karen L, additional, Majhail, Navneet S., additional, Wingard, John R., additional, Abidi, Muneer H., additional, Geller, Nancy L., additional, Wu, Juan, additional, Rizzo, J. Douglas, additional, Faber, Edward A, additional, Jim, Heather, additional, Jacobsen, Paul, additional, Horowitz, Mary M., additional, and Lee, Stephanie J., additional

Published
2014
Full Text
View/download PDF

241. Update on Comparative Analysis of Immune Reconstitution in HIV-Positive Recipients of Allogeneic and Autologous Stem Cell Transplant on the BMT CTN 0903/AMC-080 and BMT CTN 0803/AMC-071 Trials

Author

Shindiapina, Polina, Pietrzak, Maciej, Seweryn, Michal, McLaughlin, Eric, Zhang, Xiaoli, Makowski, Mat, Ahmed, Elshafa, Pearson, Rebecca, Kitzler, Rhonda, Le-Rademacher, Jennifer G., Little, Richard F, Akpek, Görgün, Ayala, Ernesto, Devine, Steven M., Kaplan, Lawrence D., Noy, Ariela, Popat, Uday R., Hsu, Jack W., Morris, Lawrence E, Mendizabal, Adam, Wachsman, William, Williams, Nita, Sharma, Nidhi, Hofmeister, Craig C, Forman, Stephen J., Navarro, Willis H., Alvarnas, Joseph C., Ambinder, Richard F., Malvestutto, Carlos, Choe, Hannah, Behbehani, Gregory, Lozanski, Gerard, Blaser, Bradley, and Baiocchi, Robert

Published
2023
Full Text
View/download PDF

242. Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma

Author

Pasquini, Marcelo C., primary, Le Rademacher, Jennifer, additional, Flowers, Christopher, additional, Lill, Michael, additional, Costa, Luciano J., additional, Shore, Tsiporah B., additional, Vaughan, William, additional, Craig, Michael, additional, Freytes, Cesar O., additional, Shea, Thomas C., additional, Horwitz, Mitchell E., additional, Fay, Joseph W., additional, Mineishi, Shin, additional, Rondelli, Damiano, additional, Mason, James, additional, Reddy, Vijay, additional, Braunschweig, Ira, additional, Ai, Weiyun, additional, Armstrong, Elizabeth, additional, Smith, Angela, additional, Zhao, Cathy, additional, Elekes, Agnes, additional, Carreras, Jeanette, additional, Kato, Kazunobu, additional, and Waller, Edmund K., additional

Published
2014
Full Text
View/download PDF

245. Low CD34 Cell Dose Is Associated With Higher Non-Relapse and Overall Mortality After Reduced Intensity Conditioning Hematopoietic Cell Transplantation For Acute Myeloid Leukemia and Myelodysplastic Syndrome

Author

Thörlén, Johan, primary, Ringdén, Olle, additional, Le Rademacher, Jennifer, additional, Battiwalla, Minoo, additional, Chen, Junfang, additional, Ho, Vincent T., additional, Kebriaei, Partow, additional, Keever-Taylor, Carolyn A., additional, Kindwall-Keller, Tamila L., additional, Lazarus, Hillard M., additional, Laughlin, Mary J., additional, Lill, Michael, additional, O’Brien, Tracey A., additional, Perales, Miguel Angel, additional, Rocha, Vanderson, additional, Savani, Bipin N., additional, Szwajcer, David, additional, Valcarcel, David, additional, and Eapen, Mary, additional

Published
2013
Full Text
View/download PDF

246. Transplantation For Myelodysplastic Syndrome Evolving From Aplastic Anemia Treated With Immunosuppressive Therapy: From The Fred Hutchinson Cancer Research Center and Center For International Bone Marrow Transplantation Research

Author

Kim, Sung-Yong, primary, Le Rademacher, Jennifer, additional, Carreras, Jeanette, additional, Antin, Joseph H., additional, Anderlini, Paolo, additional, Ayas, Mouhab, additional, Battiwalla, Minoo, additional, Kurtzberg, Joanne, additional, Nakamura, Ryotaro, additional, Eapen, Mary, additional, and Deeg, H. Joachim, additional

Published
2013
Full Text
View/download PDF

247. Provider and Center Characteristics Of US Transplant Centers and Their Association With Survival After Allogeneic Hematopoietic Cell Transplantation (HCT) In Adults: Results From a National Survey Conducted By The Center For International Blood and Marrow Transplant Research (CIBMTR)

Author

Majhail, Navneet S., primary, Payton, Tammy, additional, Mau, Lih-Wen, additional, Le Rademacher, Jennifer, additional, Chitphakdithai, Pintip, additional, Eckrich, Michael, additional, Joffe, Steven, additional, Lee, Stephanie J., additional, LeMaistre, Charles F., additional, Loberiza, Fausto R., additional, Logan, Brent R., additional, Murphy, Elizabeth A, additional, Parsons, Susan K., additional, Repaczki-Jones, Ramona, additional, Rizzo, J. Douglas, additional, Robinett, Pam, additional, and Denzen, Ellen, additional

Published
2013
Full Text
View/download PDF

248. Exercise and Stress Management Training For Patients Undergoing Autologous Or Allogeneic Hematopoietic Cell Transplantation. Results From Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902

Author

Lee, Stephanie J., primary, Le Rademacher, Jennifer, additional, Jim, Heather, additional, Syrjala, Karen L, additional, Wingard, John R., additional, Logan, Brent R., additional, Wu, Juan, additional, Majhail, Navneet S., additional, Wood, William A., additional, Rizzo, J. Douglas, additional, Geller, Nancy L., additional, Kitko, Carrie L., additional, Faber, Edward A., additional, Abidi, Muneer H., additional, Slater, Susan E., additional, Horowitz, Mary M., additional, and Jacobsen, Paul, additional

Published
2013
Full Text
View/download PDF

249. Improved Survival with Intravenous Busulfan (IV BU) Compared to Total Body Irradiation (TBI)-Based Myeloablative Conditioning Regimens: A CIBMTR Prospective Study

Author

Bredeson, Chris, primary, Le-Rademacher, Jennifer, additional, Zhu, Xiaochun, additional, Burkart, Jeanne, additional, Kato, Kazunobu, additional, Armstrong, Elizabeth, additional, Sun, Yiping, additional, Smith, Angela, additional, Ho, Vincent T., additional, McCarthy, Philip L., additional, Cooke, Kenneth R., additional, Rizzo, J. Douglas, additional, and Pasquini, Marcelo C., additional

Published
2013
Full Text
View/download PDF

250. The Effect of Transplant Center Characteristics On Survival After Pediatric Hematopoietic Cell Transplantation

Author

Eckrich, Michael J, primary, Le-Rademacher, Jennifer, additional, Rizzo, J. Douglas, additional, Baker, K. Scott, additional, Bhatla, Deepika, additional, Buchbinder, David K., additional, Cooke, Kenneth R., additional, Duerst, Reggie, additional, Gilman, Andrew, additional, Frangoul, Haydar, additional, Kapoor, Neena, additional, Kernan, Nancy A., additional, Verneris, Michael, additional, and Eapen, Mary, additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results